The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
  • Hangzhou Asian Games
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
  • Hangzhou Asian Games
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    PHOTOSTrapped along borders

  • 3

    Korea wins gold in League of Legends competition; Faker tops podium

  • 5

    VIDEOBustling Chuseok: Namsan Hanok Village immerses visitors in Korea's rich traditions

  • 7

    Pentagon's CWMD strategy document calls N. Korea 'persistent threat'

  • 9

    Builders vie for leadership in modular construction

  • 11

    Yoon hosts Chuseok luncheon for Korean atomic bomb victims in Hiroshima

  • 13

    Apple, China met to discuss Beijing's crackdown on western apps: WSJ

  • 15

    Poll shows 79% of young Koreans agree on need to improve ties with Japan

  • 17

    Second release of Fukushima wastewater to start next week

  • 19

    S. Korea cruises past N. Korea in women's basketball

  • 2

    BTS' Jungkook to drop 2nd solo single

  • 4

    Trailblazing nonagenarian artist honored for redefining Korean fiber art

  • 6

    Opposition leader Lee again proposes talks with President Yoon

  • 8

    BTS' Jungkook drops 2nd solo single

  • 10

    Are 'finfluencers' helping or harming investment community?

  • 12

    Korea fails to be included on FTSE Russell's global bond index

  • 14

    Swimmer Kim Woo-min captures 3rd gold in Hangzhou

  • 16

    INTERVIEW'Coexistence of different art hubs across Asia is necessary': Art Week Tokyo Director

  • 18

    S. Korea eliminates N. Korea in women's table tennis doubles

  • 20

    My left arm: how right-handed shooter won Asiad medal with left hand

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Sun, October 1, 2023 | 16:49
Health & Science
Will COVID-19 pills help relieve current wave of infections?
Posted : 2021-12-27 16:45
Updated : 2021-12-27 16:49
Lee Hyo-jin
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link
Medical staff wearing protective gear work in an intensive care unit for COVID-19 patients at Hyemin Hospital in Seoul, Monday. Joint Press Corps
Medical staff wearing protective gear work in an intensive care unit for COVID-19 patients at Hyemin Hospital in Seoul, Monday. Joint Press Corps

Korea to introduce Pfizer's oral treatments from January

By Lee Hyo-jin

Medical experts showed mixed reactions to whether the introduction of oral COVID-19 treatment pills, scheduled for mid-January, will be a "game changer" in the country's battle against the coronavirus.

The experts were also divided on whether enough doses for 604,000 people, which the government has secured so far, will be sufficient to curb the current wave of infections.

The Korea Disease Control and Prevention Agency (KDCA) announced Monday that it has secured enough antiviral drugs for 604,000 people, including doses for 362,000 people of Paxlovid developed by Pfizer and doses for 242,000 people of Molnupiravir from Merck.

The pills will be gradually introduced from mid-January beginning with initial supplies of Paxlovid to be used to treat patients who are at high risk of developing severe COVID-19 symptoms.

The announcement came shortly after the country's drug regulator gave Paxlovid the green light for emergency use, making it the first oral COVID-19 pill to be available in the country.

Paxlovid is administered as three co-packaged tablets ― two nirmatrelvir tablets and one ritonavir tablet ― which work together to inhibit the replication process of the coronavirus.

The Ministry of Food and Drug Safety cleared the pill for patients aged 12 and older weighing at least 40 kilograms. It said the pills should be prescribed as soon as possible after a COVID-19 diagnosis and within five days of the onset of symptoms, to be taken every 12 hours for five days.

Chon Eun-mi, a respiratory disease specialist at Ewha Womans University Mokdong Hospital, viewed the introduction of the easy-to-use pills as a major step forward in the fight against the pandemic.

New COVID-19 cases drop below 4,000 for 1st time in nearly a month
New COVID-19 cases drop below 4,000 for 1st time in nearly a month
2021-12-28 09:58  |  Health & Science

"Considering its high efficacy shown during clinical trials, ease of shipment, storage and administration, if used with the right strategy, the oral pills will much help the country tackle the COVID-19 crisis," she told The Korea Times.

Medical staff wearing protective gear work in an intensive care unit for COVID-19 patients at Hyemin Hospital in Seoul, Monday. Joint Press Corps
Food and Drug Safety Minister Kim Gang-lip speaks during a briefing on emergency use authorization for Pfizer's oral COVID-19 treatment Paxlovid, at the ministry headquarters in Osong, North Chungcheong Province, Monday. Yonhap

Unlike Paxlovid, all of the previously approved coronavirus treatments required either intravenous (IV) infusion or injection.

Chon added that the secured amount of doses for 604,000 people seems sufficient for now.

"Though initial supplies are limited, I don't expect any serious supply delays, given that generic versions of the pill will soon be manufactured in other countries."

On the other hand, Ma Sang-hyuk, vice president of the Korean Vaccine Society, gave a contrasting view.

"The amount is way too small compared to that of other countries, for instance, Japan's two million courses," Ma said, urging the authorities to make aggressive pre-purchases to avoid a repeat of vaccine supply shortage.

A course of medication refers to a period of continual treatment with a drug.

During the first few months of its COVID-19 vaccination rollout, Korea grappled with a series of supply shortages due to the government's failure to preemptively secure sufficient doses.

Ma also said, "Though the pill would be effective in preventing severe illnesses, I wouldn't call it a 'game changer.' We've learned for the past two years that vaccines and treatments alone cannot eradicate the rapidly mutating virus. Using these as tools, the government needs to draw up a detailed pandemic exit plan."

But the expert noted that the oral pills would help relieve the current shortage of hospital beds, as Korea has been seeing record-breaking numbers of patients in critical condition.

The KDCA reported 1,078 critically-ill patients for Sunday, with 4,207 new infections.

The government will announce Friday whether to extend the social distancing measures after the current ones end on Jan.3.



Emaillhj@koreatimes.co.kr Article ListMore articles by this reporter
 
miguel
wooribank
LG
Top 10 Stories
1[INTERVIEW] Risk-averse culture is forcing daring creators to flee showbiz INTERVIEWRisk-averse culture is forcing daring creators to flee showbiz
2Koreans adapt to soaring food prices Koreans adapt to soaring food prices
3[PHOTOS] Trapped along borders PHOTOSTrapped along borders
4Education ministry prohibits parents from recording classes Education ministry prohibits parents from recording classes
5[VIDEO] Bustling Chuseok: Namsan Hanok Village immerses visitors in Korea's rich traditions VIDEOBustling Chuseok: Namsan Hanok Village immerses visitors in Korea's rich traditions
6Builders vie for leadership in modular construction Builders vie for leadership in modular construction
7Value, consumer goods, financial stocks expected to gain momentum after Chuseok holiday Value, consumer goods, financial stocks expected to gain momentum after Chuseok holiday
8Are 'finfluencers' helping or harming investment community? Are 'finfluencers' helping or harming investment community?
9[INTERVIEW] ROK-US alliance is win-win partnership: KUSAF chief INTERVIEWROK-US alliance is win-win partnership: KUSAF chief
10Over 30,000 protesters march for climate actions Over 30,000 protesters march for climate actions
Top 5 Entertainment News
1[INTERVIEW] 'Coexistence of different art hubs across Asia is necessary': Art Week Tokyo Director INTERVIEW'Coexistence of different art hubs across Asia is necessary': Art Week Tokyo Director
2M+ deputy director discusses Seoul's potential to challenge Hong Kong as Asia's art hub M+ deputy director discusses Seoul's potential to challenge Hong Kong as Asia's art hub
3Trailblazing nonagenarian artist honored for redefining Korean fiber art Trailblazing nonagenarian artist honored for redefining Korean fiber art
4[INTERVIEW] With '30 Days,' Kang Ha-neul finds new level of comfort in acting INTERVIEWWith '30 Days,' Kang Ha-neul finds new level of comfort in acting
5Rwandan artists bring diversity to Seoul's art scene Rwandan artists bring diversity to Seoul's art scene
DARKROOM
  • Turkey-Syria earthquake

    Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group